Cellergy Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$22M
- Investors
-
6
Cellergy Therapeutics General Information
Description
Operator of a biotechnology company intended to transform human health. The company is making a mitochondrial product for systemic repeated administration with fully matched allogeneic purified mitochondria, in IV administration for large systemic indications such as CNS, muscle degeneration, and aging, enabling patients to help energize cells, fight degenerative diseases and enhance healthy longevity.
Contact Information
Website
www.cellergy-bio.comCorporate Office
- 13 Lilinblum
- Tel Aviv 6513202
- Israel
Corporate Office
- 13 Lilinblum
- Tel Aviv 6513202
- Israel
Cellergy Therapeutics Timeline
Cellergy Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 01-Jul-2026 | $22M | Completed | Generating Revenue | ||
| 1. Early Stage VC | 20-Nov-2025 | Completed | Generating Revenue |
Cellergy Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Shares | ||||||||
| Seed-1 Shares | ||||||||
| Seed-2 Shares | 226,939 | $0.010000 | $6.32 | $6.32 | 1x | $6.32 | 38.91% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cellergy Therapeutics Patents
Cellergy Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024226639-A1 | Mitochondria isolation from cells in suspension | Pending | 23-Feb-2023 | ||
| EP-4669326-A1 | Mitochondria isolation from cells in suspension | Pending | 23-Feb-2023 | ||
| US-20240409877-A1 | Mitochondria isolation from cells in suspension | Pending | 23-Feb-2023 | ||
| WO-2024176236-A1 | Mitochondria isolation from cells in suspension | Inactive | 23-Feb-2023 | C12N1/066 |
Cellergy Therapeutics Signals
Cellergy Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aliya Capital | PE/Buyout | Minority | ||
| Pershing Square Foundation | Not-For-Profit Venture Capital | Minority | ||
| Rotcan Holdings | Corporation | Minority | ||
| Schneider Children's VC | Venture Capital | Minority | ||
| ENKORE International Enterprises | Venture Capital | Minority |
Cellergy Therapeutics FAQs
-
When was Cellergy Therapeutics founded?
Cellergy Therapeutics was founded in 2021.
-
Where is Cellergy Therapeutics headquartered?
Cellergy Therapeutics is headquartered in Tel Aviv, Israel.
-
What is the size of Cellergy Therapeutics?
Cellergy Therapeutics has 6 total employees.
-
What industry is Cellergy Therapeutics in?
Cellergy Therapeutics’s primary industry is Biotechnology.
-
Is Cellergy Therapeutics a private or public company?
Cellergy Therapeutics is a Private company.
-
What is the current valuation of Cellergy Therapeutics?
The current valuation of Cellergy Therapeutics is .
-
What is Cellergy Therapeutics’s current revenue?
The current revenue for Cellergy Therapeutics is .
-
How much funding has Cellergy Therapeutics raised over time?
Cellergy Therapeutics has raised $25.6M.
-
Who are Cellergy Therapeutics’s investors?
Aliya Capital, Pershing Square Foundation, Rotcan Holdings, Schneider Children's VC, and ENKORE International Enterprises are 5 of 6 investors who have invested in Cellergy Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process